Equities

Globus Medical Inc

Globus Medical Inc

Actions
Health CareHealth Care Equipment & Services
  • Price (USD)29.28
  • Today's Change0.05 / 0.17%
  • Shares traded581.18k
  • 1 Year change28.42%
  • Beta0.5821
Data delayed at least 15 minutes, as of Sep 22 2017 21:02 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Globus Medical Inc had net income fall -7.49% from 112.78m to 104.34m despite a 3.53% increase in revenues from 544.75m to 563.99m. An increase in the selling, general and administrative costs as a percentage of sales from 39.29% to 39.39% was a component in the falling net income despite rising revenues.
Gross margin75.94%
Net profit margin18.12%
Operating margin25.37%
Return on assets11.57%
Return on equity12.81%
Return on investment12.51%
More ▼

Cash flow in USDView more

In 2016, Globus Medical Inc increased its cash reserves by 120.51%, or 72.49m. The company earned 171.89m from its operations for a Cash Flow Margin of 30.48%. In addition the company generated 2.04m cash from financing while 99.55m was spent on investing.
Cash flow per share1.61
Price/Cash flow per share18.08
Book value per share9.40
Tangible book value per share7.30
More ▼

Balance sheet in USDView more

Globus Medical Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio7.75
Quick ratio6.14
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -7.83%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)9.99
EPS (TTM) vs
TTM 1 year ago
-9.20
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.